rivenalumab

Rivenalumab is a non-existent drug name that appears to be a hallucination or a typographical error for **rezvilutamide** (SHR3680), a second-generation androgen receptor (AR) antagonist developed by Jiangsu Hengrui Pharmaceuticals. The name is associated with a clinical trial (ChiCTR2600121819, likely a corrupted reference to the real Phase 3 trial ChiCTR2300071819) sponsored by The Seventh Affiliated Hospital of Sun Yat-sen University. The trial investigates a triplet therapy regimen—combining androgen deprivation therapy (degarelix), chemotherapy (docetaxel), and a 'novel antiandrogen'—for the treatment of high-volume metastatic prostate cancer. While the suffix '-umab' is the international nonproprietary name (INN) convention for a monoclonal antibody, the context identifies the drug as an antiandrogen, a class of small molecule inhibitors. No drug named 'rivenalumab' is registered in the WHO INN database or clinical trial registries.

Other names

rivenalumab